Biogen submits MS drug candidate Plegridy for FDA approval

05/22/2013 | American City Business Journals

Biogen Idec has filed a biologics license application with the FDA for approval to use its interferon-based drug Plegridy as a treatment for relapsing forms of multiple sclerosis. The application was based on data from a late-stage trial indicating that Plegridy significantly reduced disease activity. Biogen also plans a European application within weeks.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID